Press Detail

PRESS RELEASE

Biotest with new management team for research and regulatory affairs

- Dr. Jörg Schüttrumpf takes over responsibility for pre-clinical research and development as new Head of Global Research

- Experienced physician and pharmaceutical manager Prof. Dr. Markus Rothenburger is assuming the position as Head of Medical/ Regulatory Affairs at the beginning of next year

Dreieich, December 13, 2012. Biotest AG is realigning the Global Research and Medical/Regulatory Affairs divisions. Dr. Jörg Schüttrumpf (38) is new Head of Global Research since the beginning of November 2012. The medical doctor (MD), who has been with Biotest since July 2012, is responsible for early research and development in the important areas immunology, haematology and intensive care. This includes new projects using recombinant technologies as well as new pre-clinical research and development projects within plasma proteins.

Biotest Chairman Prof. Dr. Gregor Schulz comments: 'We are delighted to have Dr. Schüttrumpf on board. He is the ideal candidate to head this important area. Dr. Schüttrumpf is a specialist in the fields of coagulation research and transfusion medicine, and was therefore our first choice for this position.' Before joining Biotest, Dr. Schüttrumpf's career included positions at Essen und Frankfurt am Main university hospitals as well as at the blood donor service DRK-Blutspendedienst Baden-Württemberg-Hessen. Dr. Schüttrumpf specialised in the field of transfusion medicine. He also conducted research projects over several years at the Children's Hospital of Philadelphia at the University of Pennsylvania.

In addition, the position Head of Medical/Regulatory Affairs will also be filled at the beginning of 2013. Prof. Dr. Markus Rothenburger (46) will be responsible for the clinical development of new active substances and regulatory affairs. Prof. Rothenburger worked at various hospitals for 13 years in vascular and heart surgery as well as in intensive care medicine. He is a recognised specialist, with over 150 publications in renowned scientific journals. In 2006 he moved to the pharmaceutical industry and had leading positions at companies such as Novartis and Fresenius Kabi. 'We are delighted to have recruited Prof. Dr. Rothenburger. We win an excellent medical specialist and a pharmaceutical manager with wide-ranging industry connections,' Prof. Dr. Schulz explains regarding this appointment: 'The recruitment of top professionals for both of these important positions means that we are well positioned for research and development within the management level below the Board level.'
Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of pharmaceutical and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of application of clinical immunology, haematology and intensive medicine. In its Plasma Protein portfolio Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest also researches into the development of monoclonal antibodies, including in the indications of rheumatoid arthritis and cancer of plasma cells. Biotest has more than 1.600 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart